Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Geyer

Showing results (251-260 of 278) with videos related to

Pageof 28
Sort By:
Leukemia|October 31, 2015
Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromesD A Sallman, R Komrokji, C Vaupel, et al.
Blood|August 25, 2005
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myelomaS Vincent Rajkumar, Suzanne R Hayman, Martha Q Lacy, et al.
Blood|September 30, 2006
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosisAngela Dispenzieri, Martha Q Lacy, Steven R Zeldenrust, et al.
Blood|September 30, 2006
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaNeil E Kay, Susan M Geyer, Timothy G Call, et al.
Leukemia|March 26, 2004
The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myelomaL F Porrata, M A Gertz, S M Geyer, et al.
Cancer|March 1, 2014
Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survivalJonathon B Cohen, Susan M Geyer, Gerard Lozanski, et al.
Blood Advances|April 10, 2024
Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101Tracy T Batchelor, Sharmila Giri, Amy S Ruppert, et al.
International Journal of Radiation Oncology, Biology, Physics|July 6, 2004
Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancerSteven E Schild, James A Bonner, Thomas G Shanahan, et al.
Leukemia & Lymphoma|July 9, 2025
Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201Charalambos Andreadis, Olivia Bobek, Eric D Hsi, et al.
Molecular Psychiatry|May 16, 2012
Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk predictionM Ayalew, H Le-Niculescu, D F Levey, et al.
Pageof 28

Showing results (251-260 of 278) with videos related to

Sort By:
Pageof 28
Leukemia|October 31, 2015
Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromesD A Sallman, R Komrokji, C Vaupel, et al.
Blood|August 25, 2005
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myelomaS Vincent Rajkumar, Suzanne R Hayman, Martha Q Lacy, et al.
Blood|September 30, 2006
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosisAngela Dispenzieri, Martha Q Lacy, Steven R Zeldenrust, et al.
Blood|September 30, 2006
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaNeil E Kay, Susan M Geyer, Timothy G Call, et al.
Leukemia|March 26, 2004
The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myelomaL F Porrata, M A Gertz, S M Geyer, et al.
Cancer|March 1, 2014
Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survivalJonathon B Cohen, Susan M Geyer, Gerard Lozanski, et al.
Blood Advances|April 10, 2024
Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101Tracy T Batchelor, Sharmila Giri, Amy S Ruppert, et al.
International Journal of Radiation Oncology, Biology, Physics|July 6, 2004
Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancerSteven E Schild, James A Bonner, Thomas G Shanahan, et al.
Leukemia & Lymphoma|July 9, 2025
Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201Charalambos Andreadis, Olivia Bobek, Eric D Hsi, et al.
Molecular Psychiatry|May 16, 2012
Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk predictionM Ayalew, H Le-Niculescu, D F Levey, et al.
Pageof 28